Navigation Links
Live cell imaging reveals distinct alterations of subcellular glutathione potentials
Date:4/17/2014

In the April issue of Experimental Biology and Medicine a multidisciplinary research team led by Drs. Rex Gaskins and Paul Kenis in the Institute of Genomic Biology (IGB) on the campus of the University of Illinois Urbana-Champaign describe their recent work on subcellular redox homeostasis. Intracellular reduction-oxidation reactions underlie a variety of cell functions including energy metabolism, signaling, and transcriptional processes. Due to these crucial roles in regulating normal cellular behavior, redox status has been recognized as a key area of biological research in various diseases, including cancer.

Oxidative states are generally considered to be indicative of cellular stress; however, cells inherently release harmful reactive oxygen species during energy production, neutralized by intracellular antioxidative buffering systems. The recent development of genetically-encoded fluorescent biosensors specific to glutathione (GSH), the most abundant cellular redox buffer, has facilitated the IGB research group's discovery of distinct alterations of glutathione redox potentials in the cytosol versus mitochondria within the cell.

"The highly sensitive probe Grx1-roGFP2 enabled us to monitor rapid compartmentalized changes in the glutathione redox potentials in live cells. The complex redox interactions between organelles are significant to maintaining cellular health and imbalances may contribute to the transformation of tumor cells," said Dr. Vladimir Kolossov, corresponding author.

The changes in fluorescence intensity of the probe correspond to the alterations of oxidized:reduced GSH, which is highly indicative of overall redox balance. Time lapse images collected on a Zeiss Axiovert 200M fluorescence microscope in the core imaging facility of IGB allowed real-time monitoring of the redox state in the cytosol and mitochondria of live cells.

"In modern biology mitochondria are considered to be much more than the powerhouse of the cell; they integrate multiple intracellular signals to regulate progression through the cell cycle and into apoptosis. Therefore it is vital that they maintain optimal functionality to prevent the development of abnormal cells," states co-author Jessica Beaudoin.

With this in vivo model, the research team uncovered evidence of distinct organellar perturbations in redox balance following inhibition of GSH synthesis with buthionine sulfoximine, demonstrating increased mitochondrial oxidation in response to GSH depletion compared to the cytosol. The effect was observed in multiple mammalian cell lines, including both normal and tumorigenic models. Taken together, these findings indicate different redox requirements for the glutathione thiol/disulfide redox couple within cytosol and mitochondria of resting cells and reveal distinct regulation of their redox poise in response to inhibition of glutathione biosynthesis.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Kolossov et al have utilized a genetically-encoded redox probe that has the ability to determine oxidized/reduced glutathione levels within different cellular compartments of living cells. This will be an important approach for studying redox changes in disease states including cancer, neurodegenerative disorders, cardiovascular disease, sickle cell disease and many others which are known to involve oxidative stress".


'/>"/>

Contact: Vladimir L. Kolossov
viadimer@illinois.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
2. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
3. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
4. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
5. Study examines necessity of additional imaging in PET/CT oncologic reports
6. Fox Chase researchers find no disparities in imaging before breast cancer surgery
7. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
8. Mount Sinai is first in New York state to perform new Alzheimers imaging test in clinical setting
9. Imaging agents predict breast cancer response to endocrine therapy
10. Noninvasive imaging technique may help kids with heart transplants
11. Fighting obesity with thermal imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: